PNC FINANCIAL SERVICES GROUP, INC.
Position in PRLD — Prelude Therapeutics Inc
CIK 713676
Pittsburgh, PA
Position in PRLD
as of Mar 31, 2026
· filed May 8, 2026
Position Value
$4,002
+$607 QoQ
Shares Held
1,171
0.0% QoQ
Ownership
0.001%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2024
8 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in PRLD Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026PNC FINANCIAL SERVICES GROUP, INC. holds $99,745,787 across 265 Biotechnology names. PRLD ranks #180 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
71,942 | $32,124,978 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
18,226 | $14,082,131 | |
| 3 | TECH |
BIO-TECHNE Corp
|
93,722 | $4,897,909 | |
| 4 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
12,322 | $4,076,976 | |
| 5 | MRNA |
Moderna, Inc.
|
69,883 | $3,550,054 | |
| 6 | INCY |
Incyte Corp
|
33,976 | $3,197,817 | |
| 7 | DNTH |
Dianthus Therapeutics, Inc. /DE/
|
37,360 | $3,135,250 | |
| 8 | ARGX |
Argenx SE
|
3,796 | $2,772,027 |
All Filings in PRLD
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $4,002 | 1,171 | Shares | Defined | 2026-05-08 | |
| 2025-12-31 | $3,395 | 1,171 | Shares | Defined | 2026-02-06 | |
| 2025-09-30 | $1,685 | 1,171 | Shares | Defined | 2025-11-07 | |
| 2025-06-30 | $953 | 1,180 | Shares | Defined | 2025-08-08 | |
| 2025-03-31 | $914 | 1,192 | Shares | Defined | 2025-05-09 | |
| 2024-12-31 | $81 | 64 | Shares | Defined | 2025-02-07 | |
| 2024-09-30 | $132 | 64 | Shares | Defined | 2024-11-08 | |
| 2024-06-30 | $243 | 64 | Shares | Defined | 2024-08-09 | |
| No filing history on record for this holder in this stock. | ||||||